EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Infliximab versus Cyclophosphamide for Severe Behçet’s Syndrome

David Saadoun, Georgina Maalouf, Matheus Vieira, Salim Trad, Estibaliz Lazaro, Karim Sacre, Aurelie Plessier, Thomas Sené, Isabelle Koné-Paut, Nicolas Noel, Arsène Mekinian, Marc Lambert und 21 weitere

NEJM Evidence · 22.10.2024 · 3 (11)

DOI: 10.1056/evidoa2300354 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift NEJM Evidence, erschienen am 22.10.2024. Verfasst von David Saadoun und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière University Ho…. Hauptthemen laut MEDLINE: Behcet Syndrome, Cyclophosphamide, Infliximab, Severity of Illness Index. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Behcet SyndromeCyclophosphamideInfliximabSeverity of Illness IndexAdultFemaleHumansMaleMiddle AgedBayes TheoremImmunosuppressive AgentsTreatment Outcome

Substanzen

CyclophosphamideImmunosuppressive AgentsInfliximab

Autor:innen und Institutionen

  • Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Centre national de références Maladies Autoimmunes et systémiq…
  • Department of Internal Medicine, Ambroise-Paré Hospital, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France.
  • Internal Medicine Department, Bordeaux Hospital University, Bordeaux, France.
  • CNRS-UMR 5164 Immuno ConcEpT, Bordeaux, France.
  • Department of Internal Medecine, Hôpital Haut-Lévèque, Pessac, France.
  • Department of Internal Medicine, Bichat-Claude Bernard Hospital, Paris.

Zitieren

APA

Saadoun, D., Maalouf, G., Vieira, M., Trad, S., Lazaro, E., Sacre, K., Plessier, A., Sené, T., Koné-Paut, I., Noel, N., Mekinian, A., Lambert, M., Ribeiro, E., Mirault, T., Mele, N., Dellal, A., Fain, O., Melki, I., Chiche, L., …, & Cacoub, P. (2024). Infliximab versus Cyclophosphamide for Severe Behçet’s Syndrome. NEJM Evidence, 3(11). https://doi.org/10.1056/evidoa2300354

Vancouver

Saadoun D, Maalouf G, Vieira M, Trad S, Lazaro E, Sacre K, et al. Infliximab versus Cyclophosphamide for Severe Behçet’s Syndrome. NEJM Evidence. 2024;3(11). doi:10.1056/evidoa2300354

BibTeX
@article{Saadoun2024,
  author = {Saadoun, David and Maalouf, Georgina and Vieira, Matheus and Trad, Salim and Lazaro, Estibaliz and Sacre, Karim and Plessier, Aurelie and Sené, Thomas and Koné-Paut, Isabelle and Noel, Nicolas and Mekinian, Arsène and Lambert, Marc and Ribeiro, Emmanuel and Mirault, Tristan and Mele, Nicolas and Dellal, Azeddine and Fain, Olivier and Melki, Isabelle and Chiche, Laurent and Gaudric, Julien and Redheuil, Alban and Maillart, Elisabeth and Ghembaza, Amine and Desbois, Anne-Claire and Mirouse, Adrien and Domont, Fanny and Leroux, Gaëlle and Ferfar, Yasmina and Rigolet, Aude and Viallard, Jean-François and Vautier, Mathieu and Resche-Rigon, Matthieu and Cacoub, Patrice},
  title = {Infliximab versus Cyclophosphamide for Severe Behçet’s Syndrome},
  journal = {NEJM Evidence},
  year = {2024},
  volume = {3},
  number = {11},
  doi = {10.1056/evidoa2300354}
}
Kostenlos starten →